Technotes, Publications, Technology platforms and FAQs
Publications and Technotes
ACS Biomarker aims to advance translational research by publishing high-quality data in peer reviewed journals. See our technotes for details on our measurement and analysis pipeline.
Prognostic value of circulating microRNAs on heart failure-related morbidity and mortality in two large diverse cohorts of general heart failure patients.
Bayés-Genis A. et al. Eur J Heart Fail. 2017 Sep 26
Serially measured circulating microRNAs and adverse clinical outcomes in patients with acute heart failure.
van Boven N. et al. Eur J Heart Fail. 2017 Sep 26
Circulating miRNA Analysis Guidelines
De Ronde et al. RNA. 2017 May;23(5):811-821
miR-22-3p in heart failure
Van Boven et al. Int J Cardiol. 2017 May 15;235:124-132
Circulating microRNAs: novel biomarkers and extracellular communicators in cardiovascular disease?
Creemers EE et al. Circ Res. 2012 Feb 3;110(3):483-95
MiR423-5p as a circulating biomarker for heart failure.
Tijsen et al. Circ Res. 2010 Apr 2;106(6):1035-9.
Cardio-Onco Biomarker Panel
RNA profiling platform
To obtain high quality results we have chosen the superior miRNA platform of Quantabio for our biomarker services. This platform offers a cost-effective method to measure multiple RNA molecules from a single RT reaction. The open technology provides flexibility to design your own assay primers and eliminates inefficient stem-loop priming and costly hydrolysis probes. It has been reported as one of the best miRNA profiling platforms and guarantees to deliver reliable results.